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New Insights into Atopic Dermatitis:
Role of Skin Barrier and Immune
Dysregulation
Donald YM Leung1
ABSTRACT
Atopic dermatitis (AD) is a chronic inflammatory skin disease that is often associated with the development of
food allergy and asthma. New insights into AD reveals an important role for structural abnormalities in the epi-
dermis resulting in a leaky epithelial barrier as well as chronic immune activation that contribute to the patho-
physiology of this common skin disease. Patients with AD have a predisposition to colonization or infection by
microbial organisms, most notably Staphylococcus aureus and herpes simplex virus (HSV). Measures directed
at healing and protecting the skin barrier and controlling the immune activation are needed for effective man-
agement of AD. Early intervention may improve outcomes for AD as well as reduce the systemic allergen sensi-
tization that may lead to associated allergic diseases in other organs.
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INTRODUCTION
AD is a common chronic inflammatory skin disease
that is often associated with the development of food
allergy and asthma.1 Recent studies reveal strong as-
sociations between mental health disorders and AD,
suggesting the need to effectively manage this dis-
ease for patient’s general well being.2,3 Lifetime
prevalence of AD varies worldwide from approxi-
mately 8-18%.4 A recent report in Shanghai, China re-
ported that the prevalence of AD was significantly
higher in urban areas of Shanghai compared to rural
areas of this city.5 Life style and environmental fac-
tors likely contribute to clinical expression in AD.6-9
In Japan, environmental oxidants have been impli-
cated in the changing prevalence of AD.10 Stress,
such as experienced by patients during the Great
Hanshin earthquake, has also been well documented
to exacerbate AD.11
The skin is an important interface between the host
and its environment. A leaky skin epithelial barrier
combined with abnormal immune responsiveness
likely contributes to the pathophysiology of AD.12,13
The current review will highlight recent insights into
the role of skin barrier, environmental factors and im-
mune dysfunction leading to AD. The effective treat-
ment of AD requires a multi-pronged approach involv-
ing skin barrier repair, control of skin inflammation,
identification and management of allergenic triggers,
as well as treatment of microbial infection.14
CLINICAL FEATURES AND PHENOTYPES OF
AD
New insights into mechanisms of AD should address
the key clinical features of AD as well as explain the
different phenotypes associated with this skin dis-
ease.15 The cardinal feature of AD is severe pruritus
that is associated with cutaneous hyperreactivity to
various environmental stimuli including exposure to
food and inhalant allergens, irritants, changes in
physical environment (including pollution, humidity,
etc), microbial infection and stress. After patients
scratch their skin, an acute eczematoid eruption
(with erythematous papules) appears, and lichenifica-
tion with epidermal hyperplasma results from chronic
eczema. This is in contrast to patients with chronic
idiopathic urticaria that develop hives but not eczema
after scratching, and highlights potential differences
in mechanisms between chronic idiopathic urticaria
(e.g. autoantigen induced mast cell degranulation
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Table　1　Different phenotypes of atopic dermatitis
Early onset vs late onset
Mild vs severe eczema
Increased IgE vs non-atopic
S. aureus infection/colonization
Disseminated viral or fungal infections e.g. EH, molluscum
contagiosum, Malassezia
The atopic march
without skin barrier dysfunction) as opposed to AD
which stems from skin barrier dysfunction, and in-
creased penetration of antigens which drive mononu-
clear cell infiltration and chronic skin inflammation.16
Multiple overlapping, but distinct, clinical pheno-
types of AD exist (Table 1). Most infants who present
with mild AD will outgrow their skin disease in later
childhood. However, a group of difficult to manage
patients exist who have early onset eczema, with se-
vere life long AD. Adult onset AD also exist although
it is unclear whether these may be patients that had
eczema during infancy, then went into a prolonged
remission only to have relapse of eczema later in life
since recall history, in such cases, may not be reli-
able. Over 50% but certainly not all AD have associ-
ated asthma, allergic rhinitis or food allergy. Approxi-
mately 80% of AD patients have elevated serum IgE
andor immediate skin test reactivity to allergens but
20% of AD have no IgE to food or inhalant allergens.
However, it is possible that such intrinsic or non-
atopic patients may have IgE or autoreactive T cells
to autoallergens or microbial antigens which are not
routinely measured.17-20 Other AD subsets exist in-
cluding those who are prone to skin infection such as
Staphylococcus aureus skin infections or eczema her-
peticum.21,22 Although up to 90% of AD may have
problems with S. aureus skin colonization, actual
overt skin infections requiring systemic antibiotic
treatment affect less than 50% of AD. Less than 5% of
AD are predisposed to eczema herpeticum or eczema
vaccinatum.23 These different phenotypes likely arise
from a complex combination of mutations and epige-
netic effects on genes controlling protein expression
in the skin barrier, innate and adaptive immune re-
sponse with a strong environmental influence.
EPITHELIAL SKIN BARRIER ABNORMALITIES
IN AD
Multi-Functional Role of Filaggrin
The skin barrier plays a critical role in host defense
against microbial invasion, and allergen penetration.
The stratum corneum represents the culmination of a
complex epithelial cell differentiation process in
which keratinocytes produce a strong but resilient
physical barrier of cross-linked matrix containing lip-
ids and proteins which minimize water loss and pro-
tects the body from allergen or microbial penetration.
Recent studies indicate that defects in epidermal bar-
rier function contribute greatly to triggering and per-
petuation of skin inflammation in AD.12,13 The skin in
AD is characterized by increased transepidermal
water loss, and a defect in terminal keratinocyte dif-
ferentation leading to reduced levels of ceramides,
filaggrin and antimicrobial peptides.24-29 Concomi-
tantly increased protease activity and proflammatory
cytokine release resulting from increased endoge-
nous keratinocyte and mast derived proteases re-
leased in atopic skin as well as exogenous proteases
from environmental allergens, such as dust mites, or
S. aureus results in skin barrier breakdown.30,31
In normal subjects, formation of the cornified cell
envelope involves dephosphorylation and cleavage of
profilaggrin by serine proteases ending in the release
of filaggrin.13 Filaggrin aggregates the keratin cy-
toskeleton to facilitate the flattening of keratinocytes
in the outermost skin layer. Additionally, other pro-
teins encoded by genes in the epidermal differentia-
tion complex including loricrin and involucrin are es-
sential components of the epidermal barrier.32 As the
water content of the stratum corneum drops, filaggrin
is proteolyzed into pyrrolidine carboxylic acid and
trans-urocanic acid which contribute to the composi-
tion of natural moisturizing factor (NMF) and ac-
counts in part for corneocyte hydration.33 Filaggrin
deficiency in AD contributes to decreased hydration
of the stratum corneum and increased transepidermal
water loss.34
Importantly, filaggrin breakdown products play an
important role in acidifying the stratum corneum and
decreased generation of filaggrin metabolites in-
creases the pH of the stratum corneum leading to ac-
tivation of a number of serine proteases and may
thereby increase barrier breakdown.35 A recent in vi-
tro study demonstrated that S. aureus growth rate
and cell density were affected by the acidic filaggrin
breakdown products urocanic acid and pyrrolidone
carboxylic acid.36 Lower pH was associated with re-
duced expression of secreted and cell wall-associated
proteins, including proteins involved in S. aureus ad-
herence to the skin such as clumping factor B and fi-
bronectin binding protein A, as well as protein A,
which is involved in immune evasion.
The critical role of skin barrier dysfunction as a
causative factor in AD is supported by reports demon-
strating that loss-of-function mutations in the filaggrin
gene (FLG) are the most significant and well repli-
cated risk factor for development of AD.13,37 FLG mu-
tations increase the risk for persistent dry skin,38 en-
hance percutaneous immune responses39 and is asso-
ciated with increased expression of IL-1 in the stra-
tum corneum of patients with AD.40 Filaggrin has
also been found to protect against staphylococcal al-
pha toxin mediated keratinocyte cell death.41 The
skin barrier abnormality caused by FLG mutations is
also associated with increased serum 25-hydroxy vita-
Atopic Dermatitis
Allergology International Vol 62, No2, 2013 www.jsaweb.jp 153
Fig.　1　Immunologic pathways involved in different phases of atopic dermatitis. Published with permission from: 
Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of TH2/TH22 cytokines and selective epider-
mal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 2012; 130: 1344-54.
min D concentrations.42
Filaggrin null mutations affect a minority of sub-
jects with AD. Reduction in filaggrin are often ob-
served even in the skin of AD patients who have no
detectable FLG null mutations. In this regard, in-
tragenic copy number variation within the filaggrin
gene has been demonstrated to contribute to the risk
of AD with a dose-dependent effect.43 Furthermore, a
variety of cytokines have been found to reduce filag-
grin expression including IL-4, IL-13, TNF and IL-
25.44-46 Proteomic profiling of AD skin have revealed
found that multiple other proteins related to the skin
barrier (filaggrin-2, corneodesmosin, desmoglein-1,
desmocollin-1, and transglutaminase-3) and genera-
tion of natural moisturizing factor (arginase-1,
caspase-14, and gamma-glutamyl cyclotransferase)
were expressed at significantly lower levels in le-
sional, as compared to nonlesional, sites of patients
with AD.24 These studies are supported by genomic
and histologic profiling studies of AD skin revealing
broad termination epidermal differentiation defects.29
Thus, a combination of genetic and acquired factors
contribute to reduced epidermal differentiation, and
downregulation of epidermal barrier function.
Tight Junction Abnormalities: A Second Defect
in the Physical Barrier of AD
Gene expression profiling of nonlesional epithelium
from patients with extrinsic AD, nonatopic subjects,
and patients with psoriasis recently revealed a strik-
ingly lower level of the tight junction proteins,
claudin-1 and claudin-23, in patients with AD.47 Tight
junctions are found on opposing membranes of stra-
tum granulosum keratinocytes directly below the
stratum corneum and thereby form a second physi-
cial barrier in the epidermis (Fig.1). They are made
up of a complex of adhesive proteins that control the
passage of fluids and solutes through the paracellular
pathway. The nonlesional epithelium of AD subjects
has been shown to have bioelectric abnormalities in-
dicative of a tight junction defect which could be the
consequence of reduced levels of claudin-1 (CLDN1),
a key tight junction adhesive protein.47 This is consis-
tent with earlier work in CLDN1 knockout mice that
established the importance of epidermal tight junc-
tions and claudin-1. CLDN1 knockout mice died
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within 24 hours of birth with severe dehydration and
increased epidermal permeability as measured by
dye studies and transepidermal water loss.48 The sus-
ceptibility of human keratinocytes to HSV-1 infection
is inversely related to the degree of cell-cell contact
and confluency maintained by claudin-1 levels.49 In
AD, an inverse correlation was found between
CLDN1 expression and markers of Th2 polarity (total
eosinophil counts and serum total IgE).
IMMUNE RESPONSES IN AD
Once the 2 physical barriers (filaggrin, tight junc-
tions) are breached, a rapid, innate immune response
must be initiated to prevent further microbial inva-
sion and replication. Keratinocytes and antigen pre-
senting cells in the skin express a number of innate
immune receptors also referred to as pattern recogni-
tion receptors of which Toll like receptors (TLRs) are
the best known.12,50 Stimulation of TLRs by microbes
or tissue injury leads to release of antimicrobial pep-
tides, cytokines and chemokines and enhanced
strength of TJs to limit penetration of allergens and
microbes. Patients with AD have been found to have
reduced TLR function. Studies of patients with AD re-
veal that they are deficient in their production of
keratinocyte derived antimicrobial peptides needed
to control S. aureus and viral replication.12 This may
predispose to microbial colonization and chronic skin
inflammation.
The adaptive immune response in AD is associated
with increased expression of the Th2 cyctokines (IL-
4, IL-13 and IL-31) and the Th22 cytokine, IL-2251 dur-
ing the acute phase of AD (Fig. 1). These cytokines
reduce epidermal differentiation and thereby contrib-
ute to reduced filaggrin expression and anti-microbial
peptide expression. IL-31 induces severe pruritus in
addition to its inhibitory effects on epidermal differen-
tiation.52 The complex cytokine profile that evolves af-
ter formation of acute AD lesions, includes a rise in
interferon-gamma which induces apoptosis of kerati-
nocytes.53 These effects, however, can be counterbal-
anced by IL-10 which controls dendritic cell induced
T cell reactivity in the skin.54,55 Corticotropin-
releasing hormone (CRH) has recently been found to
downregulate IL-10 production by adaptive forkhead
box protein 3-negative regulatory T cells in AD.56,57
Although AD is known as a Th2- and Th22 medi-
ated inflammatory skin disease whereas psoriasis is
known as a Th1Th17 mediated skin disease,58 there
may be other AD subsets. Indeed, IL-17 expression
has been reported in mouse models of eczema.59 Re-
cently, a comparative transcriptomic analyses of AD
and psoriasis revealed evidence for increased IL-17
gene expression and shared neutrophilic inflamma-
tion in these two skin diseases.60
Dendritic cells are recognized as one of the key
cells involved in the initiation of T cell responses in
various skin diseases.61 In AD, dendritic cells such as
Langerhans cells and inflammatory dendritic epider-
mal cells express increased levels of FceRI as well as
reduced interferon responses.62 Blocking H1 hista-
mine receptor signaling of dendritic cells dampened
allergen driven skin immune responses.63 Epidermal
keratinocytes in AD express increased thymic stro-
mal lymphopoietin (TSLP), a cytokine that enhances
dendritic cell driven Th2 cell differentiation.64,65 IL-25
and IL-33, released from multiple cell types including
keratinocytes and type 2 innate lymphoid cells, also
augment Th2 responses and can activate eosinophils
and mast cells.66 Mechanical injury, allergen expo-
sure and microbial infection increases TSLP, IL-25
and IL-33 thus increasing Th2 responses.67,68
A critical link between the barrier defect in AD pa-
tients with FLG mutations and Th2 polarization can
explained by enhanced allergen penetration through
the damaged epidermis accompanied by increased
production of TSLP, IL-25 and IL-33 by keratinocytes
and other skin cells leading to a Th2-type milieu.
TSLP, in particular, may act as a “master switch” for
allergic inflammation since it has effects on a number
of key cells involved in cutaneous allergic inflamma-
tion, including mast cells, basophils and eosino-
phils.64 The clinical observation that topical cal-
cineurin inhibitors and topical corticosteroids can
partially correct the barrier defect in AD supports the
concept that inflammation or immune activation can
downregulate the barrier function in AD and that
there is cross talk between the epidermal barrier and
the immune system.69
DEFINING AD SUBSETS FOR BETTER MAN-
AGEMENT APPROACHES
Recent advances in the genetics and pathophysiology
of AD have contributed to our understanding of endo-
types in AD.15 Endotypes have been proposed in
asthma which is recognized to be a complex disease
or syndrome that can be divided into distinct disease
entities based on distinct pathophysiological mecha-
nisms, referred to as “asthma endotypes”.70 The im-
portance of eventually defining endotypes in AD is
that these new subtypes can be used in clinical study
design and drug development to target existing and
novel therapies to patients most likely to benefit from
a mechanism-based treatment. In the future, AD may
be characterized by genotype, biomarkers reflecting
immune polarization and the clinical phenotype.
Multiple clinical phenotypes have been described
in AD (Table 1). Childhood AD is common, with
more than 60% of patients having onset of disease
within the first 2 years of age.71 Complete clearance
of childhood AD occurs in approximately 50% of pa-
tients. The remainder have recurrences in adoles-
cence and adulthood. Adult onset of AD can also oc-
cur without a history of childhood AD.72 In all forms
of AD, clinical phenotypes can be further stratified ac-
cording to mild vs severe forms and their various trig-
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Fig.　2　Comparison of clinical and biophysical features of atopic dermatitis patients with (ADFLG) and without 
(ADNON-FLG) fi laggrin mutations. Published with permission from: McAleer MA, Irvine AD. The multifunctional role 
of fi laggrin in allergic skin disease. J Allergy Clin Immunol 2013; 131: 280-91.
ADFLG Clinical Features
Palmar Hyperlinearity
Clinical Features
No Palmar Hyperlinearity
Less Persistent
Less Allergic Sensitization
Lower Risk of Asthma
Severe Decrease in Natural
Moisturizing Factor (NMF)
More Persistent
Allergic Sensitization
Risk of Asthma
Severity
Eczema Herpeticum
pH
IL-1β
Biophysical Features
Mild Decrease in Natural
Moisturizing Factor (NMF)
pH Lower Compared to ADFLG
IL-1β Low Compared to ADFLG
Biophysical FeaturesADNON-FLG
gers including bacterial and viral infection. There has
also been considerable interest in the group who un-
dergo the atopic march which refers to AD patients
with associated food allergy who develop asthma or
allergic rhinitis later in childhood as this provides an
opportunity to develop preventative approaches to
prevent respiratory allergy. High systemic sensitiza-
tion to food and inhalant allergens may occur in AD
due to penetration of these environmental allergens
through the damaged skin barrier of these patients.
Genetic studies have revealed the association of
mutations which are beginning to distinguish certain
endotypes of AD. The strongest data involves identifi-
cation of patients with filaggrin mutations.13 AD pa-
tients with homozygous filaggrin null mutations or
compound heterozygotes, as compared to patients
with normal filaggrin gene expression, have early on-
set of skin disease, more persistent, and severe ec-
zema which can be complicated by eczema herpeti-
cum13,73 (Fig. 2). They also often have palmar hyper-
linearity, greater risk of allergen sensitization, a his-
tory of food allergy and develop asthma.74,75 These
patients also have an increased pH in their stratum
corneum which may predispose them to S. aureus
colonization.36 Patients who have heterozygous filag-
grin mutations have an intermediate phenotype.
Although filaggrin mutations are the most signifi-
cant and well replicated genetic mutation associated
with AD, filaggrin mutations account for only a minor-
ity of total AD although up to 50% of severe AD can
have filaggrin mutations.13 Many other genes involv-
ing skin barrier responses as well as the innate and
adaptive immune response have also been implicated
reinforcing the concept that AD is a complex genetic
disease.15,76-78 These include various genes control-
ling skin barrier function such as mutations in the
serine protease inhibitor Kazal-type 5 (SPINK5)
gene, which encodes the protease inhibitor lym-
phoepithelial Kazal-type-related inhibitor (LEKTI).79
In a murine model of AD generated by epidermal
LEKTI deficiency,80 severe eczema and increased
TSLP production was observed mimicking some of
the critical features in AD. Genetic variants in CLDN1
are also associated with risk of eczema herpeticum in
AD subjects.49 Furthermore, excluding subjects with
a FLG mutation strengthened the association of
CLDN1 mutations with susceptibility to EH. These
data suggest that both stratum corneum and TJ epi-
dermal barrier defects participate in mechanisms that
increase the susceptibility of subjects with ADEH+ to
widespread cutaneous infections with HSV.
Gene variants may also contribute to the abnormal
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Fig.　3　Stepwise approach for management of AD according to disease severity.
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innate immune response and Th2 adaptive responses
found in AD. These include the observation that cer-
tain Toll-like receptor 2 (TLR2) variants are associ-
ated with severe AD.81 A recent study found an in-
creased association between genes encoding TSLP
and its receptors, IL7R, with risk of eczema herpeti-
cum.82 Association between gene variants encoding
for the Th2- driving cytokines IL-483 and IL-13,84 and
the down-stream transcription factor STAT685 sup-
port the importance of Th2 responses in AD. A com-
mon haplotype encoding IL-31, a cytokine which in-
duces severe pruritus, has been reported to be asso-
ciated with the intrinsicnon- IgE-associated form of
AD.86 These findings point to the importance of both
barrier and immune response genes in driving the
complex phenotype of AD.
Given the complex genetic picture of AD, the de-
velopment of biomarkers is important to assess the fi-
nal immune polarized pathways that may exist in vari-
ous AD subsets. The best biomarkers for AD cur-
rently define patients who are Th2 polarized vs those
who are not. Approximately 80% of AD have elevated
serum IgE levels. These patients often have in-
creased eosinophilia and serum levels of the Th2
chemokine, thymus and activation regulated
chemokine (TARC) levels. Additional markers are
needed to better monitor AD patients with so-called
intrinsic AD. It is noteworthy, however, that studies
of so-called intrinsic AD patients who lacked IgE to
conventional inhalant and food allergens did have de-
tectable serum IgE to autoantigens in the skin and
microbial antigens from bacterial and fungi that colo-
nize the skin.19,87 Therefore a wider range of IgE
screens to various exogenous and endogenous anti-
gens is warranted to determine potential triggers of
AD as it may have an important impact on pathways
triggering allergic skin inflammation. Overall the vari-
ous causes of a leaky epithelial skin barrier leading to
disruption of the microbial flora, a defective innate
immune response and enhanced Th2 adaptive im-
mune abnormalities that influences the physical bar-
rier provides some explanation for the different AD
subsets leading to complex clinical phenotypes.
TREATMENT AND MANAGEMENT OF AD
The management of AD requires a systematic, multi-
pronged approach. This includes skin hydration and
barrier repair, topical anti-inflammatory medications,
control of infection and elimination of exacerbating
factors (including allergens, irritants and emotional
triggers) taking into consideration that AD is a het-
erogeneous disease requiring an individualized ap-
proach for each patient. Treatment should utilize a
stepwise approach that is dependent on the severity
of skin disease (reviewed in reference 14).
The first step in AD is reduced skin barrier func-
tion resulting from lack of structural proteins and lip-
ids in the epidermis (Fig. 3). This leads to enhanced
water loss and dry skin. Except for the mildest cases,
skin hydration will often require warm soaking baths
Atopic Dermatitis
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for at least 10 minutes followed by the application of a
moisturizer. Moisturizers, available in the form of
creams, and ointments should be recommended as
first-line therapy. When using the more occlusive
ointments, consider pre-wetting the skin before its ap-
plication. In patients with moderate to severe AD, ce-
ramide rich or filaggrin containing creams may be
considered.
The second step in AD is skin inflammation. This is
invariably present in patients with moderate to severe
AD, even involving their non-lesional skin, since a de-
fective barrier allows allergens and microbes to pene-
trate the skin thereby triggering the immune and in-
flammatory response. In AD that is not controlled by
emollients alone, a topical anti-inflammatory agent
should be used. Low-potency corticosteroids are rec-
ommended for maintenance therapy, whereas me-
dium and high-potency corticosteroids should be
used for the treatment of clinical exacerbation over
short periods of time. Proactive treatment with inter-
mittent medium potency topical steroids and cal-
cineurin inhibitors have been shown to reduce AD re-
lapses.88
Jensen et al.69 looked at transpidermal water loss,
as well as several other parameters of epidermal bar-
rier including stratum corneum hydration and dye
penetration and showed improvement in all parame-
ters when AD patients were treated with both a topi-
cal steroid and a topical calcineurin inhibitor. Both
treatments normalized markers of epidermal cell dif-
ferentiation. Of note, while expression of filaggrin
was reduced in untreated patients with AD, it was
completely restored on treatment with either anti-
inflammatory therapy. Coal tar, which has weaker
anti-inflammatory effects has also been shown to im-
prove skin barrier in AD.89
Another important long-term strategy for patient
management is the identification of factors that trig-
ger AD including foods (particularly in infants and
young children), aeroallergens, stress and infection.
Patients with AD have a unique propensity to be colo-
nized or infected by a number of microbial organ-
isms.1 To assess the relationship between skin micro-
biota and disease progression, Kong et al.90 recently
performed 16S ribosomal RNA bacterial gene se-
quencing on DNA from serial skin sampling of chil-
dren with AD. In AD, the proportion of Staphylococcus
sequences, particularly S. aureus, was greater during
disease flares than at baseline or post-treatment, and
correlated with worsened disease severity. Interest-
ingly, various AD treatments were associated with in-
creased bacterial diversity. S. aureus infection may
also predispose AD patients to disseminated viral
skin infections.91 Control of infection generally in-
volves appropriate use of antibiotics. It is important to
treat only infections that are clinically overt as most
AD patients are colonized with S. aureus and overuse
of antibiotics can lead to MRSA infection.22 In pa-
tients prone to S. aureus infection, consider using
bleach baths.92
Pruritus is the cardinal symptom of AD that ad-
versely impacts quality of life and makes it difficult to
control the skin disease since scratching itself in-
duces skin rashes in these patients. Improved skin
barrier preventing allergenmicrobial penetration
and effective anti-inflammatory therapy is associated
with reduced pruritus. Conventional H-1 antihista-
mine therapy is frequently ineffective but recent stud-
ies suggest H4 blockers may be more important in
the itch of AD.93 The unclear role of antihistamines in
controlling itch of AD reflects the wide variety of me-
diators implicated in pruritus in AD.94 IL-31, which is
highly pruritic when overexpressed in animal models
of AD, has also been found to be increased in AD. Ir-
respective of the atopic phenotype, serum IL-31 levels
have been shown to correlate with disease activity in
AD.95
In AD patients who are refractory to conventional
treatment approaches, a number of alternative strate-
gies have been proposed including the use of cy-
closporine, methotrexate, azathioprine, immunoad-
sorption, IL-6 blockade, conventional immunotherapy
and ultraviolet light.96-102 Vitamin D deficiency is be-
ing increasingly recognized as playing a role in aller-
gic diseases.103 Vitamin D appears to also have sev-
eral beneficial effects in AD including the upregula-
ton of antimicrobial peptides involved in control of in-
fection as well as induction of T regulatory cells
which can suppress inflammation.104 Preliminary re-
sults of a clinical trial in children with AD treated with
oral vitamin D in a randomized, controlled trial
showed clinical improvement versus placebo.105
Since current treatment approaches are not curative,
there is considerable interest in also studying ap-
proaches to prevent AD.106 The use of probiotic ther-
apy or bacterial lysates early in the course of illness
remains an area of active investigation.107,108
CONCLUSIONS
Patients with AD have genetic mutations that affect
their skin barrier function and immune responses
triggered by unique environmental triggers. A cross-
talk occurs such that the immune response can ad-
versely impair skin barrier function in AD. Clinically,
this results in intensely pruritic, inflamed skin that al-
lows penetration of irritants and allergens and predis-
poses patients to colonization and infection by micro-
bial organisms. Insights into the complex relationship
between skin barrier and immune abnormalities
should lead to more targeted therapy for AD and as-
sociated infectious complications. New methods to
categorize distinct phenotypes and polarized immune
pathways of AD may lead to novel early intervention
strategies that could also interrupt the development
of asthma and allergic disorders.
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